Economic Impact
The Biopharmaceutical Industry Boosts the U.S. Economy
The biopharmaceutical industry is a major driver of innovation and economic growth both within the U.S. and globally. The industry’s growth and resilience lead to jobs for significant numbers of highly skilled, highly productive and highly paid workers across the country. Sustaining this important driver of the U.S. economy is a set of robust and long-standing pro-innovation policies that include strong intellectual property protections, a well-functioning and evidence-based regulatory system, support for research and development and other policies that recognize both the societal and economic impacts of medical innovation.
PhRMA engaged TEConomy Partners, LLC, to develop an independent estimate of the economic contributions of the U.S. biopharmaceutical industry and its closely integrated supply chain in 2022.
Explore all fact sheets at the Industry Economic Impact page for the entire U.S., the 50 states, the District of Columbia and Puerto Rico on this map or download the full report on the 2022 Economic Impact of the U.S. Biopharmaceutical Industry.
Download the fact sheet on the Economic Impact in
Alabama
AL
Alaska
AK
Arizona
AZ
Arkansas
AR
California
CA
Colorado
CO
Connecticut
CT
Delaware
DE
District of Columbia
DC
Florida
FL
Georgia
GA
Hawaii
HI
Illinois
IL
Indiana
IN
Iowa
IA
Kansas
KS
Kentucky
KY
Louisiana
LA
Maine
ME
Maryland
MD
Massachusetts
MA
Michigan
MI
Minnesota
MN
Mississippi
MS
Missouri
MO
Montana
MT
Nebraska
NE
Nevada
NV
New Hampshire
NH
New Jersey
NJ
New Mexico
NM
New York
NY
North Carolina
NC
North Dakota
ND
Ohio
OH
Oklahoma
OK
Oregon
OR
Pennsylvania
PA
Puerto Rico
PR
Rhode Island
RI
South Carolina
SC
South Dakota
SD
Tennessee
TN
Texas
TX
Utah
UT
Vermont
VT
Virginia
VA
Washington
WA
West Virginia
WV
Wisconsin
WI
Wyoming
WY
Economic Impact
Download the fact sheet on the Economic Impact in
Alabama_Eco Impact One Pager 2022_3.pdf
https://cdn.aglty.io/phrma/fact-sheets/economic-impact/Alaska_Eco Impact One Pager 2022_3.pdf
Arizona_Eco Impact One Pager 2022_3.pdf
Arkansas_Eco Impact One Pager 2022_3.pdf
Colorado_Eco Impact One Pager 2022_2.pdf
California_Eco Impact One Pager 2022_2.pdf
Connecticut_Eco Impact One Pager 2022_3.pdf
Delaware_Eco Impact One Pager 2022_2.pdf
DC_Eco Impact One Pager 2022_2.pdf
Florida_Eco Impact One Pager 2022_2.pdf
Georgia_Eco Impact One Pager 2022_3.pdf
Hawaii_Eco Impact One Pager 2022_2.pdf
Illinois_Eco Impact One Pager 2022_3.pdf
Indiana_Eco Impact One Pager 2022_2.pdf
Iowa_Eco Impact One Pager 2022_2.pdf
Kansas_Eco Impact One Pager 2022_2.pdf
Kentucky_Eco Impact One Pager 2022_3.pdf
Louisiana_Eco Impact One Pager 2022_2.pdf
Maine_Eco Impact One Pager 2022_2.pdf
Maryland_Eco Impact One Pager 2022_2.pdf
Massachusetts_Eco Impact One Pager 2022_3.pdf
Michigan_Eco Impact One Pager 2022_2.pdf
Minnesota_Eco Impact One Pager 2022_2.pdf
Mississippi_Eco Impact One Pager 2022_2.pdf
Missouri_Eco Impact One Pager 2022_2.pdf
Montana_Eco Impact One Pager 2022_2.pdf
Nebraska_Eco Impact One Pager 2022_3.pdf
Nevada_Eco Impact One Pager 2022_2.pdf
New Hampshire_Eco Impact One Pager 2022_2.pdf
New Jersey_Eco Impact One Pager 2022_2.pdf
New Mexico_Eco Impact One Pager 2022_2.pdf
New York_Eco Impact One Pager 2022_2.pdf
North Carolina_Eco Impact One Pager 2022_2.pdf
Ohio_Eco Impact One Pager 2022_2.pdf
North Dakota_Eco Impact One Pager 2022_2.pdf
Oklahoma_Eco Impact One Pager 2022_3.pdf
Oregon_Eco Impact One Pager 2022_2.pdf
Pennsylvania_Eco Impact One Pager 2022_3.pdf
Puerto Rico_Eco Impact One Pager 2022_2.pdf
Rhode Island_Eco Impact One Pager 2022_3.pdf
Tennessee_Eco Impact One Pager 2022_3.pdf
Texas_Eco Impact One Pager 2022_2.pdf
Utah_Eco Impact One Pager 2022_2.pdf
Vermont_Eco Impact One Pager 2022_2.pdf
Virginia_Eco Impact One Pager 2022_3.pdf
Washington_Eco Impact One Pager 2022_2.pdf
Creating jobs
The U.S. biopharmaceutical industry directly employed more than one million workers in 2022, and with its substantial employment multiplier of 4.69, the industry supports more than 3.8 million additional U.S. jobs for a total employment impact of more than 4.9 million jobs supported across the U.S. economy.
The industry has been able to weather economic downturns, demonstrated by solid 30.8% growth since 2015, providing important stability to both the production of life saving medicines and to the U.S. and regional economies in which it operates.
With average annual wages and benefits in 2022 of more than $157,000 per worker — over $60,000 more than the average U.S. manufacturing job, and more than twice the U.S. average across all industries — biopharmaceutical industry jobs are both high-wage and high-quality.
Overall Economic Contribution
The U.S. biopharmaceutical industry exceeded $800 billion in direct output in 2022, and with the ripple effect of this production throughout the U.S. economy, supported an additional $850 billion in output through its suppliers and other sectors of the economy, for a total of more than $1.65 trillion. This combined, total output impact represents 3.6% of all U.S. output.
Although just a snapshot of the sector’s total impact, these findings demonstrate the importance of a strong and vibrant biopharmaceutical industry in helping other businesses grow and contributing to robust local and national economies.
Through its research, production and overall operations, the U.S. biopharmaceutical industry directly accounts for 1.6% of U.S. GDP (i.e., its “value added”). Including the economic activity driven in other sectors of the economy the industry generates and supports more than $880 billion in value added within the economy, or 3.4% of U.S. GDP.
STEM
In an increasingly competitive global environment, it is critical that the U.S. strengthen its standing in science, technology, engineering and math (STEM) education to stay ahead of other countries, like China and Singapore, in order to continue create more high-wage research and development (R&D) and advanced manufacturing jobs in the U.S. and sustain and grow the economic contributions of R&D-intensive industries like the innovative biopharmaceutical sector. The U.S. biopharmaceutical sector is the envy of the world supporting a total of nearly 4.5 million jobs across the economy, and contributing $1.2 trillion in economic output when direct and indirect effects are considered in the U.S. alone.
The U.S. currently faces a growing gap in STEM skills compared to countries such as Japan, China, and parts of Europe, which are making substantial public investments in STEM education and other key areas of competitiveness, including growing their R&D, manufacturing, and other infrastructure investments. As an industry rooted in science and innovation, the biopharmaceutical industry is particularly concerned about the current shortage of highly-skilled workers in the U.S., a gap that is expected to grow substantially over the next decade leading individual biopharmaceutical companies to deepen their commitment to improving the state of STEM education at all levels in the U.S.
Enhancing Today’s STEM Workforce to Ensure Tomorrow’s New Medicines, reveals how innovative biopharmaceutical companies and their foundations are partnering with colleges and universities to foster the next generation of STEM workers. According to the report, biopharmaceutical companies and their foundations have partnered with 53 individual colleges and universities in support of 75 educational programs emphasizing hands-on, experiential learning through a focus on industry-relevant curricula. These partnerships are happening at all levels of the postsecondary pipeline from various certification and associate’s programs though master’s and doctoral programs and worker training programs.
Related Resources
Vaccines: A high-return investment for America’s health and our nation's economy